CV Lattes
ResearcherID
ORCID
Google Scholar Citations
Universidade Estadual Paulista (UNESP). Campus de Botucatu. Instituto de Biociências (IBB) (Institutional affiliation from the last research proposal) Birthplace: Brazil
Molecular and Cellular Biologist - investigate mechanisms involved in muscle wasting diseases. Our research group is using cellular, molecular, and bioinformatics approaches to better understand the pathways that mediate protein loss associated with muscle wasting diseases including cancer and heart failure. We are particularly interested in how noncoding regulatory RNAs, such microRNAs, regulate muscle atrophy. The long-term goal is to not only to better dissect the function and mechanisms by which genes regulates muscle wasting, but also translate this information to identify new drug targets to support the development of new therapeutic strategies. (Source: Lattes Curriculum)
| News published in Agência FAPESP Newsletter about the researcher |
| More itemsLess items |
| TITULO |
| Articles published in other media outlets ( ): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |
Cachexia is a multifactorial syndrome highly associated with specific tumor types, but the causes of the variation in the prevalence and severity of cachexia are still unknown. Although circulating plasma mediators (soluble cachectic factors) derived from the tumor have been implicated with the pathogenesis of the syndrome, these associations were generally based on the plasma concentrati…
Cardiac cachexia (CC) is a common complication of heart failure (HF) associated with muscle wasting and poor patient prognosis. Although different mechanisms have been proposed to explain muscle wasting during CC, its pathogenesis is still not understood. Here, we described an integrative analysis between miRNA and mRNA expression profiles of muscle wasting during CC. Global gene expressi…
(Only some records are available in English at this moment)
Lung cancer is the second most diagnosed type of cancer worldwide and the most lethal, accounting for 18% of all cancer deaths in 2020. Although chemotherapy is widely used in treatment, variability in patient responses to the same treatment remains a significant challenge. One reason for this variability is the difference in tumor transcriptional profiles among patients. Studies have com…
Cancer-associated cachexia is a syndrome characterized by muscle mass and adipose tissue loss, which affects approximately 80% of advanced cancer patients. Circulating plasma mediators, called cachexia-mediating factors, have been implicated in the pathogenesis of the syndrome. These factors have a specific expression profile for each tumor type, and are associated with cachexia prevalenc…
Cancer-associated cachexia is a syndrome characterized by involuntary weight loss, mainly due to loss of muscle mass. It is a multifactorial metabolic syndrome associated with specific tumor types, but the variation causes in the prevalence and severity of cachexia are still unknown. RNA sequencing (RNA-Seq) revolutionized transcriptomic studies and allowed a better understanding of the m…
Lung cancer is the second most prevalent and deadly cancer, accounting for 18% of all cancer deaths in 2020. Among the histological types of lung cancer, non-small cell lung cancer is the most common (~85%), with the subtype lung adenocarcinoma (LUAD) standing out. This subtype originates from lung glandular cells and affects ~40% of patients. The treatment is established according to tum…
Muscular diseases are changes in skeletal muscle tissue caused by various defective structural proteins, deregulated molecular pathways and other mechanisms. Several research groups study these muscular alterations in order to clarify all the processes responsible for this condition that modify the skeletal muscles and leads to a progressive lethal degeneration of this tissue. The complex…
Cachexia is a metabolic syndrome characterized by an ongoing loss of skeletal muscle mass that cannot be fully reversed by conventional nutritional support, most found in patients with advanced cancer. The cancer cachexia molecular pathways are not completely known, however, advances in genomic, transcriptomic and proteomic studies in cancer have helped in understanding the relationship o…
(Only some records are available in English at this moment)
Cancer-associated cachexia is a debilitating syndrome characterized by weight loss and muscle wasting, profoundly affecting patients' quality of life and prognosis. The prevalence of cachexia among cancer patients is estimated to range from 15% to 70%, with variations depending on the specific tumor type. The syndrome significantly compromises the response to radiotherapy and chemothera…
Pro-inflammatory cytokines such as Tumor Necrosis Factor alpha (TNF) has been implicated in the pathogenesis of skeletal muscle atrophy in cachexia, a metabolic syndrome commonly associated with many chronic systemic inflammatory diseases such as cancer and AIDS. Although the up-regulation of mRNA levels in response to TNF signaling has been studied extensively in the context of immune ac…
The skeletal muscle atrophy is a common phenomenon in many chronic systemic diseases such as sepsis, chronic heart failure, chronic obstructive pulmonary disease, chronic kidney disease, diabetes, AIDS and cancer. These diseases can be accompanied by a complex metabolic syndrome characterized by muscle wasting, known as cachexia. The molecular pathways responsible for cachexia are not com…
(Only some records are available in English at this moment)
| 9 / 6 | Completed research grants |
| 3 / 3 | Ongoing scholarships in Brazil |
| 16 / 15 | Completed scholarships in Brazil |
| 4 / 4 | Completed scholarships abroad |
| 32 / 28 | All research grants and scholarships |
| Associated processes | |